Flubromazolam (JYI-73) is a novel synthetic depressant substance of the benzodiazepine, and specifically, the triazolobenzodiazepine class which produces anxiolytic, disinhibiting, sedative, muscle relaxant, and memory suppressing effects when administered. It is incredibly potent (active in the microgram range) with an unusually long 18 hour duration. Thus, it poses comparatively higher risks than other designer benzodiazepines, due to its ability to produce strong sedation and amnesia even at a very low threshold dosage.
Flubromazolam has been noted for its potential use in the short-term treatment of anxiety, insomnia, acute seizures, and the sedation of hospitalized patients. however, it is currently exclusively sold by online research chemical vendors for use as a recreational psychoactive substance and has not been formally studied.
Any comments regarding its pharmacology are purely speculation based upon the subjective effects it induces and its structural similarity to triazolam, pyrazolam and other benzodiazepines.
It is worth noting that the sudden discontinuation of benzodiazepines can be potentially dangerous or life-threatening for individuals using regularly for extended periods of time, sometimes resulting in seizures or death. It is highly recommended to taper one’s dose by gradually lowering the amount taken each day for a prolonged period of time instead of stopping abruptly.